Last reviewed · How we verify
NCT03351569
Intravenous Immunoglobulin for Unverricht-Lundborg Disease.
Phase 3 trial testing Intravenous immunoglobulin in Unverricht-Lundborg Disease in 1 participant. Status unknown.
6 December 2016
Quick facts
| Lead sponsor | Azienda Socio Sanitaria Territoriale di Mantova |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 9 December 2015 |
| Primary completion | 6 December 2016 |
| Estimated completion | 30 December 2017 |
Drugs / interventions tested
- Intravenous immunoglobulin — full drug profile →
Conditions studied
- Unverricht-Lundborg Disease — all drugs for Unverricht-Lundborg Disease →
Sponsor
Azienda Socio Sanitaria Territoriale di Mantova
Who can join
Adults 18 to 25, male only, with Unverricht-Lundborg Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Single patient randomized double blind trial to assess whether intravenous immunoglobulin can improve the clinical outcome of a case suffering from Unverricht-Lundborg disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03351569
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intravenous immunoglobulin
Trials testing the same drug.
- NCT07202052 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) · Phase 2, PHASE3 · recruiting
- NCT05104762 — IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients · Phase 2, PHASE3 · completed
- NCT04035135 — A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) · Phase 1 · completed
- NCT03401073 — IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3 · Phase 2 · completed
- NCT03630211 — Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis · Phase 2 · recruiting
Other recruiting trials for Unverricht-Lundborg Disease
Currently open trials in the same condition.
- NCT06593951 — Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1) · recruiting
Other Azienda Socio Sanitaria Territoriale di Mantova trials
Trials by the same sponsor.
- NCT04569188 — Convalescent Plasma in COVID-19 Elderly Patients · Phase 2 · completed
- NCT05157165 — Convalescent Plasma in Hospitalized COVID-19 Patients · no longer available
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03351569 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Socio Sanitaria Territoriale di Mantova
- Last refreshed: 27 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03351569.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing